Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Summary

This phase III study is an open-label extension study to be conducted at approximately 21 investigational sites across 3 countries. The study will evaluate the long-term safety and tolerability of Chronocort in participants aged 16 years and over when used as treatment for Congenital Adrenal Hyperplasia (CAH).

Timeline

Start

2022-04-01

Primary completion

2026-01-15

Completion

2026-01-15

Drugs

Indications